Stockscreener 앱 받기
4.99
2.92%
-0.15
시간 외 거래:
4.99
전일 마감가:
$5.14
열려 있는:
$5.16
하루 거래량:
712.24K
Relative Volume:
0.44
시가총액:
$471.27M
수익:
$824.50M
순이익/손실:
$-365.90M
주가수익비율:
-1.2623
EPS:
-3.9531
순현금흐름:
$-25.60M
1주 성능:
+1.63%
1개월 성능:
+8.95%
6개월 성능:
-38.09%
1년 성능:
-32.57%
1일 변동 폭
$4.98
$5.31
1주일 범위
$4.85
$5.36
52주 변동 폭
$3.76
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
명칭
Myriad Genetics Inc
전화
801-584-3600
주소
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.99 | 485.44M | 824.50M | -365.90M | -25.60M | -3.9531 |
TMO
Thermo Fisher Scientific Inc
|
524.57 | 195.48B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
194.54 | 138.36B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.01 | 46.31B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
122.09 | 34.18B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
335.23 | 32.95B | 3.17B | 642.63M | 516.49M | 10.77 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-21 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 개시 | Craig Hallum | Buy |
| 2024-12-10 | 개시 | UBS | Neutral |
| 2024-12-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Underperform |
| 2024-05-08 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 재개 | Piper Sandler | Neutral |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Underweight |
| 2023-05-23 | 업그레이드 | Goldman | Sell → Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 개시 | Stephens | Equal-Weight |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Sell |
| 2019-09-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-07-29 | 다운그레이드 | Needham | Strong Buy → Hold |
| 2019-07-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-03-12 | 재확인 | Needham | Strong Buy |
| 2019-01-03 | 개시 | Needham | Strong Buy |
| 2018-11-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 개시 | Goldman | Sell |
| 2018-01-22 | 재확인 | Barclays | Equal Weight |
| 2018-01-05 | 개시 | BTIG Research | Buy |
| 2017-10-02 | 재개 | Leerink Partners | Mkt Perform |
| 2017-08-09 | 재확인 | Barclays | Equal Weight |
| 2017-02-08 | 업그레이드 | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 개시 | Deutsche Bank | Sell |
| 2016-10-10 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
모두보기
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Myriad (MYGN) up 4.1% since last earnings report: Can it continue? - MSN
Myriad Genetics (MYGN) to Present at AACR Annual Meeting 2026 - GuruFocus
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 - ChartMill
Myriad Genetics, Inc. (NASDAQ:MYGN) Sees Significant Decline in Short Interest - MarketBeat
Myriad Genetics (NASDAQ: MYGN) COO has 1,069 shares withheld for RSU taxes - Stock Titan
Tax withholding trims Myriad Genetics (MYGN) CSO stake by 946 shares - Stock Titan
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by TD Cowen - MarketBeat
[ARS] MYRIAD GENETICS INC SEC Filing - Stock Titan
Myriad Genetics (NASDAQ: MYGN) sets 2026 votes and outlines cancer-focused growth - Stock Titan
Myriad Genetics Expands MyChoice Test Access for Prostate Cancer Patients in Japan - National Today
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan - Bitget
Japan clears Myriad test for prostate cancer patients using Lynparza - Stock Titan
GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026 - Yahoo Finance
Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y - MSN
Sectors Review: What is the next catalyst for Myriad Genetics IncPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now? - MSN
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Lobbying Update: $30,000 of TIBER CREEK GROUP ON BEHALF OF MYRIAD GENETICS INC. lobbying was just disclosed - Quiver Quantitative
Myriad Genetics Underscores Commitment to Cancer Care - GlobeNewswire
Aberdeen Group plc Purchases 246,748 Shares of Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad brings 4 SGO studies, including ovarian recurrence data - Stock Titan
Can Myriad Genetics Inc maintain its current growth rate2026 Opening Moves & Long Hold Capital Preservation Tips - baoquankhu1.vn
Trend Report: Can Myriad Genetics Inc maintain its current growth rate2026 Opening Moves & Long Hold Capital Preservation Tips - baoquankhu1.vn
Market Outlook: Whats next for Myriad Genetics Inc stockMarket Trend Report & AI Optimized Trade Strategies - baoquankhu1.vn
MYGN Technical Analysis | Trend, Signals & Chart Patterns | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance UK
Myriad Genetics | SCHEDULE 13G/A: Others - Moomoo
BlackRock (NYSE: MYGN) holds 7.98M shares, 8.5% stake reported - Stock Titan
Myriad Genetics Q4 2025 Results: Revenue Beat, Raised GuidanceNews and Statistics - IndexBox
Myriad Genetics And 2 Other Penny Stocks To Watch Closely - Yahoo Finance
Myriad Genetics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Myriad Genetics: Market Pricing in Failure as Catalysts Build for Re-Rating - Bitget
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Myriad Genetics Inc (MYD.HA) Stock Price, News, Quote & History - ca.finance.yahoo.com
3 Healthcare Stocks with Open Questions - Yahoo Finance
Myriad Genetics: SOTP Suggests The Company Is Undervalued - Seeking Alpha
Myriad Genetics, Inc. (MYD.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know - Yahoo Finance
Vanguard (MYGN) amendment shows 0 shares; subsidiaries disaggregate holdings - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Myriad Genetics launches Prequel Prenatal Screen using AMPLIFY technology for early chromosomal risk detection - Traders Union
Myriad Genetics (MYGN) CSO has shares withheld to cover RSU taxes - Stock Titan
Myriad Genetics (MYGN) COO has 2,055 shares withheld to cover taxes - Stock Titan
Myriad Genetics (MYGN) CFO uses 549 shares for RSU tax withholding - Stock Titan
Myriad Genetics Inc (MYGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.57%
0.03%
자본화:
|
볼륨(24시간):